D6070c00005-A Phase 1B/2 Study To Evaluate The Safety, Pharmacokinetics, And Clinical Activity Of Oleclumab (Medi9447) With Or Without Durvalumab In Combination With Chemotherapy In Subjects With Metastatic Pancreatic Ductal Adencarcinoma
Posted Date: Jun 11, 2019
- Investigator: Olugbenga Olowokure
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The goal of this study is to assess the safety and tolerability of oleclumab plus durvalumab in combination with chemotherapy administered in subjects with metastatic PDAC.
Criteria:
To Be Eligible: Patient Must Be 18 Years Of Age Or Older, Weight Over 35Kg, Diagnosed With Pancreatic Adenocarcinoma, Nonpregnant And Nonbreastfeeding No Other Anticancer Therapy Within 21 Days, No Venous Thrombosis, Heart Attack, Or Strokes Within Past 3 Months
Keywords:
Pancreatic Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com